Exponent's Q2 2023 showed a 9.7% increase in revenues before reimbursements, reaching $129.7 million, and earnings per diluted share increased to $0.50. Growth was driven by demand for reactive offerings and increased demand in the chemicals and life sciences sectors.
Total revenues increased by 7.6% to $140.2 million compared to the second quarter of 2022.
Revenues before reimbursements increased by 9.7% to $129.7 million compared to the second quarter of 2022.
Net income was $25.7 million, or $0.50 per diluted share.
The company's engineering and other scientific segment represented 83% of the Company’s revenues before reimbursements.
Exponent is maintaining its revenue and margin guidance for the full 2023 fiscal year.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance